A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorEli Lilly and Company
About this trial
The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 4 months and will include 2 stays in the Clinical Research Unit (CRU), each lasting 3-5 nights.
Eligibility criteria
Qualifiers
Are Japanese participants assigned male at birth (AMAB) or assigned female at birth (AFAB) who agree to contraception requirements or participants who are individuals not of childbearing potential (INOCBP).
Have a body mass index greater than or equal to (≥)25 kilograms per square meter (kg/m²)
Have had a stable weight for the 3 months prior to screening. Stable weight is defined as less than 5 percent (%) body weight change.
Disqualifiers
Have known allergies to related compounds of macupatide or eloralintide, or any components of the formulations.
Have a history of significant atopy, including severe allergic manifestations, or clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions.
Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders, within the last 3 years, that would present a safety risk or may significantly impair the participant's ability to comply with study procedures.
Have been diagnosed with Type 1 or Type 2 diabetes mellitus.
Trial design
Treatments tested in this trial
- Macupatide
- Eloralintide
- Placebo
Treatment groups
60 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov